Previous 10 | Next 10 |
— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer — — Ton Logtenberg, Ph.D., to step down after 16 years of leadership — — Transition to occur December 31, 2019 — UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2019 ...
Merus N.V. (NASDAQ: MRUS), a clinical-stage bispecific antibody company developing Biclonics(R), has closed an underwritten public offering of 5,462,500 of its common shares, which includes 712,500 additional shares per the full exercise of the over-allotment option granted to the underwriters...
Merus (NASDAQ: MRUS ): Q3 GAAP EPS of -€0.35 beats by €0.15 . More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Bic...
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offeri...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics ® , today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shar...
Gainers: Tiffany & Co. (NYSE: TIF ) +31% . Xunlei Limited (NASDAQ: XNET ) +27% . Datasea (NASDAQ: DTSS ) +25% . comScore (NASDAQ: SCOR ) +24% . Fitbit (NYSE: FIT ) +23% . Aquestive Therapeutics (NASDAQ: AQST ) +23% . ChinaNet Online Holdings (NASDAQ: CNET ) +20% . Libbey (...
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Of nine patients enrolled across the MCLA-128 Early Acc...
One out of every eight women in the United States will develop breast cancer, according to Breastcancer.org. Of those, about 25% will have an aggressive type called "HER2-positive," which also recurs at higher rates. The human epidermal growth factor receptor 2 (HER2) gene produces proteins tha...
UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length h...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...